

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61K 31/535, 31/135</p>	<p>A1</p>	<p>(11) International Publication Number: WO 99/15176 (43) International Publication Date: 1 April 1999 (01.04.99)</p>
<p>(21) International Application Number: PCT/US98/18114 (22) International Filing Date: 1 September 1998 (01.09.98) (30) Priority Data: 60/059,629 23 September 1997 (23.09.97) US (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): HEILIGENSTEIN, John, Harrison [US/US]; 1202 West 56th Street, Indianapolis, IN 46228 (US). (74) Agents: TITUS, Robert, D. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).</p>		<p>(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>
<p>(54) Title: TREATMENT OF OPPOSITIONAL DEFIANT DISORDER</p> <p>(57) Abstract</p> <p>Norepinephrine reuptake inhibitors are used to treat oppositional defiant disorder.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

TREATMENT OF OPPOSITIONAL DEFIANT DISORDER

The invention belongs to the fields of pharmaceutical chemistry and psychiatric medicine, and provides a method of treatment of the psychiatric disorder known as oppositional defiant disorder.

Children and adolescents suffering from oppositional defiant disorder exhibit a pattern of hostile, defiant, and negative behavior more often than is commonly observed in other individuals of the same mental age. They are argumentative with adults, are often angry and resentful, frequently lose their temper, swear, defy rules and requests from adults, and deliberately engage in annoying behavior. They also tend to not see themselves as a problem, but rather justify their behavior as a response to unreasonable circumstances.

Oppositional defiant disorder (ODD) is many times treated with the same therapies employed for the treatment of Attention-deficit Hyperactivity Disorder (ADHD), e.g., methylphenidate (Ritalin™), which exhibits noradrenergic and dopaminergic effects. Gross has demonstrated that certain ODD symptoms may be ameliorated by augmentation of standard ADHD therapies with buspirone in certain patients (Gross, *J. Am. Acad. Child Adolesc. Psychiatry*, 34(10), 1260 (1995)). Many patients are refractory to these treatments, or discontinue treatment due to intolerable side effects. Furthermore, due to the high potential for substance abuse in oppositional defiant disorder patients, the use of stimulants such as methylphenidate is problematic.

The need for a safe and effective treatment for oppositional defiant disorder, without the disadvantages of current therapies, continues to be a concern of the psychiatric community.

-2-


The present invention provides a method of treating oppositional defiant disorder comprising the administration to a patient in need of such treatment of an effective amount of a norepinephrine reuptake inhibitor.

5 Many compounds, including those discussed at length below, are norepinephrine reuptake inhibitors, and no doubt many more will be identified in the future. In the practice of the present invention, it is intended to include reuptake inhibitors which show 50% effective concentrations
10 of about 1000 nM or less, in the protocol described by Wong *et al.*, *Drug Development Research*, 6, 397 (1985). The norepinephrine reuptake inhibitors useful for the method of the present invention are characterized in being selective for the inhibition of neurotransmitter reuptake relative to
15 their ability to act as direct agonists or antagonists at other receptors. Norepinephrine reuptake inhibitors useful for the method of the present invention include, but are not limited to:

Tomoxetine, (R)-(-)-N-methyl-3-(2-methylphenoxy)-
20 3-phenylpropylamine, is usually administered as the hydrochloride salt. Tomoxetine was first disclosed in U.S. Patent #4,314,081. The word "tomoxetine" will be used here to refer to any acid addition salt or the free base of the molecule. See, for example, Gehlert, *et al.*, *Neuroscience*
25 *Letters*, 157, 203-206 (1993), for a discussion of tomoxetine's activity as a norepinephrine reuptake inhibitor;

The compounds of formula I:

-3-



I

wherein X is C₁-C₄ alkylthio, and Y is C₁-C₂ alkyl or a pharmaceutically acceptable salt thereof. The compounds of formula I were described in U.S. Patent 5,281,624, of Gehlert, Robertson, and Wong, and in Gehlert, et al., *Life Sciences*, 55(22), 1915-1920, (1995). The compounds are there taught to be inhibitors of norepinephrine reuptake in the brain. It is also explained that the compounds exist as stereoisomers, and that they accordingly include not only the racemates, but also the isolated individual isomers as well as mixtures of the individual isomers. For example, the compounds of formula I include the following exemplary species:

- 15 N-ethyl-3-phenyl-3-(2-methylthiophenoxy)propyl-amine benzoate;
- (R)-N-methyl-3-phenyl-3-(2-propylthiophenoxy)-propylamine hydrochloride;
- (S)-N-ethyl-3-phenyl-3-(2-butylthiophenoxy)propyl-amine;
- 20 N-methyl-3-phenyl-3-(2-ethylthiophenoxy)propyl-amine malonate;
- (S)-N-methyl-3-phenyl-3-(2-tert-butylthiophenoxy)-propylamine naphthalene-2-sulfonate;
- 25 (R)-N-methyl-3-(2-methylthiophenoxy)-3-phenyl-propylamine;

Reboxetine (Edronax[™]), 2-[α -(2-ethoxy)phenoxy-benzyl]morpholine, is usually administered as the racemate. It was first taught by U.S. Patent 4,229,449, which describes its utility for the treatment of depression.

-4-

Reboxetine is a selective norepinephrine reuptake inhibitor. The term "reboxetine" will be used here to refer to any acid addition salt or the free base of the molecule existing as the racemate or either enantiomer;

5 Duloxetine, N-methyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine, is usually administered as the hydrochloride salt and as the (+) enantiomer. It was first taught by U.S. Patent 4,956,388, which shows its high potency. The word "duloxetine" will be used here to refer
10 to any acid addition salt or the free base of the molecule;

Venlafaxine is known in the literature, and its method of synthesis and its activity as an inhibitor of serotonin and norepinephrine uptake are taught by U.S. Patent 4,761,501. Venlafaxine is identified as compound A
15 in that patent; and

Milnacipran (N,N-diethyl-2-aminomethyl-1-phenylcyclopropanecarboxamide) is taught by U.S. Patent 4,478,836, which prepared milnacipran as its Example 4. The patent describes its compounds as antidepressants. Moret et
20 al., *Neuropharmacology* 24, 1211-19 (1985), describe its pharmacological activities as an inhibitor of serotonin and norepinephrine reuptake.

All of the U.S. patents which have been mentioned above in connection with compounds used in the present
25 invention are incorporated herein by reference.

A preferred duloxetine enteric formulation is a pellet formulation comprising a) a core consisting of duloxetine and a pharmaceutically acceptable excipient; b) an optional separating layer; c) an enteric layer comprising
30 hydroxypropylmethylcellulose acetate succinate (HPMCAS) and a pharmaceutically acceptable excipient; d) an optional finishing layer. The following example demonstrates the preparation of a preferred such formulation.

-5-

Example

10 mg Duloxetine base/capsule

Bill of Materials

Beads

5	Sucrose - starch nonpareils, 20-25 mesh	60.28 mg
	Duloxetine layer	
	Duloxetine	11.21
	Hydroxypropylmethylcellulose	3.74
10	Separating layer	
	Hydroxypropylmethylcellulose	2.51
	Sucrose	5.00
	Talc, 500 mesh	10.03
	Enteric layer	
15	HPMCAS, LF grade, Shin-Etsu Chemical Co., Tokyo, Japan	25.05
	Triethyl citrate	5.00
	Talc, 500 mesh	7.52
	Finishing layer	
20	Hydroxypropylmethylcellulose	8.44
	Titanium dioxide	2.81
	Talc	<u>Trace</u>
		141.60 mg

- 25 The duloxetine layer was built up by suspending duloxetine in a 4% w/w solution of the hydroxypropylmethylcellulose in water, and milling the suspension with a CoBall Mill (Fryma Mashinen AG, Rheinfelden, Switzerland) model MS-12. A fluid bed dryer with a Wurster column was used to
- 30 make this product, at a batch size of 1.0 kg. The separating layer was added from a 4% w/w solution of the hydroxypropyl-methylcellulose in water, in which the sucrose was also dissolved.

-6-

In order to prepare the enteric coating suspension, purified water was cooled to 10°C and the polysorbate, triethyl citrate and silicone emulsion were added and dispersed or dissolved. Then the HPMCAS and talc were added and agitated until homogeneity was obtained, and the HPMCAS was fully neutralized by addition of ammonium hydroxide until solution of the polymer was complete. To this suspension, a carboxymethylcellulose aqueous solution, 0.5% w/w, was added and blended thoroughly. The enteric suspension was maintained at 20°C during the coating process. The enteric suspension was then added to the partially completed pellets in the Wurster column at a spray rate of about 15 ml/min, holding the temperature of the inlet air at about 50°C. The product was dried in the Wurster at 50°C when the enteric suspension had been fully added, and then dried on trays for 3 hours in a dry house at 60°C. A finishing layer was then applied which consisted of a 4.5% w/w/ hydroxypropylmethyl-cellulose solution containing titanium dioxide and propylene glycol as plasticizer. The pellets were completely dried in the fluid bed dryer and then were then filled in size 3 gelatin capsules.

While all compounds exhibiting norepinephrine reuptake inhibition are useful for the method of the present invention, certain are preferred. It is preferred that the norepinephrine reuptake inhibitor is selective for norepinephrine over other neurotransmitters. It is also preferred that the norepinephrine reuptake inhibitor is selected from tomoxetine, reboxetine, or a compound of formula I. It is especially preferred that the norepinephrine reuptake inhibitor be selected from tomoxetine, reboxetine, or (R)-N-methyl-3-(2-methylthiophenoxy)-3-phenylpropylamine.

-7-

It will be understood by the skilled reader that most or all of the compounds used in the present invention are capable of forming salts, and that the salt forms of pharmaceuticals are commonly used, often because they are more readily crystallized and purified than are the free bases. In all cases, the use of the pharmaceuticals described above as salts is contemplated in the description herein, and often is preferred, and the pharmaceutically acceptable salts of all of the compounds are included in the names of them.

Many of the compounds used in this invention are amines, and accordingly react with any of a number of inorganic and organic acids to form pharmaceutically acceptable acid addition salts. Since some of the free amines of the compounds of this invention are typically oils at room temperature, it is preferable to convert the free amines to their pharmaceutically acceptable acid addition salts for ease of handling and administration, since the latter are routinely solid at room temperature. Acids commonly employed to form such salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids, such as *p*-toluenesulfonic acid, methanesulfonic acid, oxalic acid, *p*-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid and the like. Examples of such pharmaceutically acceptable salts thus are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate,

-8-

chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, b-hydroxybutyrate, glycollate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate, mandelate and the like. Preferred pharmaceutically acceptable salts are those formed with hydrochloric acid.

10 Administration

 The dosages of the drugs used in the present invention must, in the final analysis, be set by the physician in charge of the case, using knowledge of the drugs, the properties of the drugs in combination as determined in clinical trials, and the characteristics of the patient, including diseases other than that for which the physician is treating the patient. General outlines of the dosages, and some preferred dosages, can and will be provided here.

20 Tomoxetine: from about 5 mg/day to about 100 mg/day; preferably in the range from about 5 to about 70 mg/day; more preferably from about 10 to about 60 mg/day; and still more preferably from about 10 to about 50 mg/day;

 Compounds of formula I: from about 0.01 mg/kg to about 20 mg/kg; preferred daily doses will be from about 0.05 mg/kg to 10 mg/kg; ideally from about 0.1 mg/kg to about 5 mg/kg;

 Reboxetine: from about 1 to about 30 mg, once to four times/day; preferred, from about 5 to about 30 mg once/day;

30 Duloxetine: from about 1 to about 30 mg once/day; preferred, from about 5 to about 20 mg once/day;

-9-

Venlafaxine: from about 10 to about 150 mg once-thrice/day; preferred, from about 25 to about 125 mg thrice/day; and

5 Milnacipran: from about 10 to about 100 mg once-twice/day; preferred, from about 25 to about 50 mg twice/day.

10 All of the compounds concerned are orally available and are normally administered orally, and so oral administration is preferred. However, oral administration is not the only route or even the only preferred route. For example, transdermal administration may be very desirable for patients who are forgetful or petulant about taking oral medicine. The drugs may also be administered by the percutaneous, intravenous, intramuscular, intranasal or
15 intrarectal route, in particular circumstances. The route of administration may be varied in any way, limited by the physical properties of the drugs and the convenience of the patient and the caregiver.

20 The best description of oppositional defiant disorder is the diagnostic criteria published by the American Psychiatric Association in the DSM-III-R (Diagnostic and Statistical Manual of Mental Disorders, Third Edition-Revised (1987)), as follows.

25 **Diagnostic criteria for Oppositional Defiant Disorder**

A. A disturbance of at least six months, during which at least five of the following are present:

- (1) often loses temper
- (2) often argues with adults
- 30 (3) often actively defies or refuses adult requests or rules, e.g., refuses to do chores at home

-10-

- 5 (4) often deliberately does things that
annoy other people, e.g., grabs other
children's hats
- (5) often blames others for his or her own
mistake
- (6) is often touchy or easily annoyed by
others
- (7) is often angry and resentful
- 10 (8) is often spiteful or vindictive
- (9) often swears or uses obscene language
- B. Does not meet the criteria for Conduct
Disorder, and does not occur exclusively
during the course of a psychotic disorder,
Dysthymia, or a Major Depressive, Hypomanic,
15 or Manic Episode.

Patients suffering from Oppositional Defiant
Disorder also commonly suffer concomitantly from Attention-
deficit Hyperactivity Disorder. The patient will benefit
20 from the use of norepinephrine reuptake inhibitors in the
amelioration of the symptoms of Oppositional Defiant
Disorder regardless of this or other co-morbid conditions.
Furthermore, a patient suffering from Oppositional Defiant
Disorder and Attention-deficit Hyperactivity Disorder will
25 receive benefit in the amelioration of symptoms of both
conditions through the method of the present invention.

The method of the present invention is effective
in the treatment of patients who are children or
adolescents, and there is no significant difference in the
30 symptoms or the details of the manner of treatment among
patients of different ages. In general terms, however, for
purposes of the present invention, a child is considered to
be a patient below the age of puberty, and an adolescent is

-11-

considered to be a patient from the age of puberty up to about 18 years of age.

Inhibition of norepinephrine reuptake

5 The ability of compounds to inhibit the reuptake of norepinephrine may be measured by the general procedure of Wong, *et al.*, *supra*.

 Male Sprague-Dawley rats weighing 150-250 gm are decapitated and brains are immediately removed. Cerebral
10 cortices are homogenized in 9 volumes of a medium containing 0.32 M sucrose and 10 mM glucose. Crude synaptosomal preparations are isolated after differential centrifugation at 1000 x g for 10 minutes and 17,000 x g for 28 minutes. The final pellets are suspended in the same medium and kept
15 in ice until use within the same day.


 Synaptosomal uptake of ³H-norepinephrine is determined as follows. Cortical synaptosomes (equivalent to 1 mg of protein) are incubated at 37°C for 5 minutes in 1 mL Krebs-bicarbonate medium containing also 10 mM glucose, 0.1 mM
20 iproniazide, 1 mM ascorbic acid, 0.17 mM EDTA and 50 nM ³H-norepinephrine. The reaction mixture is immediately diluted with 2 mL of ice-chilled Krebs-bicarbonate buffer and filtered under vacuum with a cell harvester (Brandel, Gaithersburg, MD). Filters are rinsed twice with
25 approximately 5 mL of ice-chilled 0.9% saline and the uptake of ³H-norepinephrine assessed by liquid scintillation counting. Accumulation of ³H-norepinephrine at 4°C is considered to be background and is subtracted from all measurements. The concentration of the test compound
30 required to inhibit 50% of the ³H-norepinephrine accumulation (IC₅₀ values) are determined by linear regression analysis.

-12-

We claim:

1. A method of treating oppositional defiant disorder comprising administration to a patient in need of such treatment an effective amount of a norepinephrine reuptake inhibitor.

2. A method of Claim 1 wherein the norepinephrine reuptake inhibitor is selected from the group consisting of tomoxetine, reboxetine, duloxetine, venlafaxine, milnacipran, and a compound of formula I:



I

wherein X is C₁-C₄ alkylthio, and Y is C₁-C₂ alkyl or a pharmaceutically acceptable salt thereof.

3. A method of Claim 2 wherein the norepinephrine reuptake inhibitor is tomoxetine, reboxetine, or a compound of formula I.

4. A method of Claim 3 wherein the norepinephrine reuptake inhibitor is tomoxetine.

5. A method of Claim 3 wherein the norepinephrine reuptake inhibitor is tomoxetine hydrochloride.

6. A method of Claim 3 wherein the norepinephrine reuptake inhibitor is reboxetine.

7. A method of Claim 3 wherein the norepinephrine reuptake inhibitor is (R)-N-methyl-3-(2-methylthiophenoxy)-3-phenylpropylamine.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/18114

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/535, 31/135

US CL :514/239.2, 649, 651

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/239.2, 649, 651

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, MEDLINE, HCAPLUS, EMBASE- compounds within the claims in the treatment of ODD or psychological disorders associated with anger, aggressiveness, defiance etc.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Database Medline, US National Library of Medicine, (Bethesda, MD, USA), No. 92317484, BARKLEY, R. A. et al., 'Adolescents with attention deficit hyperactivity disorder: mother-adolescent interactions, family beliefs and conflicts, and maternal psychopathology.' Journal of Abnormal Child Psychology. Abstract, June 1992, Vol. 20, No. 3, pages 263-288, see entire document.	1-7
Y	US 5,658,590 A (HEILIGENSTEIN et al.) 19 August 1997, entire document.	1-7
Y	US 4,229,449 A (MELLONI et al.) 21 October 1980, the abstract, column 18, lines 20-32, and column 46, line 25.	1-3 and 6

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

23 OCTOBER 1998

Date of mailing of the international search report

04 NOV 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

M. MOEZIE

Telephone No. (703) 308-1235